Abstract:Recently, gene therapy has been become a promising approach to cure hemophilia A, a most common recessive bleeding disease. The aim of this study was to determine the perspective of lentiviral vector in hemophilia A gene therapy in vitro and in NOD/SCID mice. Lentivirus transfer vector pXZ9/BDDFVIII containing human B-domain-deleted Factor VIII-IRES-eGFP coding sequence and mock control pXZ9 were constructed. Lentivirus was prepared by co-transfecting 3 plasmids into 293FT cells. 293FT, HLF, human bone marrow mesenchymal stem cells and Chang-liver cells were transfected with the prepared virus. Coagulant activity of human FVIII, human FVIII antigen, human FVIII mRNA transcription and genomic integration were assayed by ELISA, one-step method, RT-PCR and PCR after infection. Lentiviral particles were concentrated by ultracentrifugation and NOD/SCID mice were transfected via portal vein injection. Human FVIII antigen in mouse blood plasma was analyzed by ELISA. eGFP expression was observed by fluorescent microscopy and human FVIII transcription in mouse liver was analyzed by RT-PCR at one month after transduction. The results showed that the high titer of recombinant virus was prepared and used to efficiently transduce the target cells in vitro. At 72 h after transfection, high levels of FVIII activity and FVIII antigen were detected. Human FVIII gene transcription could be detected in the liver of NOD/SCID mice received lentiviral particles carrying FVIII gene. Mouse hepatocytes were transfected with recombinant lentivirus efficiently in vivo. Human FVIII level in mouse blood plasma reached to (49 ± 6) mU, (54 ± 8) mU and (23 ± 4) mU at 72 h, one week and one month after transfection respectively. It is concluded that the lentiviral particles carrying BDDhFVIII gene can high efficiently transfect the target cells both in vitro and in vivo, and the transfected target cells can secrete hFVIII efficiently. The sustained expression of human FVIII in NOD/SCID mice is observed after lentivirus transfection via portal vein injection.

Skeletal Muscle-Specific Expression of Human Blood Coagulation Factor IX Rescues Factor IX Deficiency Mouse by AAV-mediated Gene Transfer.

Muscle Injection of Raav/mfix to Secrete Clotting Factor IX Corrects the Hemorrhagic Tendencies in Hemophilia B Mice

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

High Expression of Human Clotting Factor Ix Cdna in Myoblasts C2c12 Cells and C3h Mice

Expression Of Human Factor Ix Gene In Murine Plasma Through Lentiviral Vector-Infected Haematopoietic Stem Cells

A Study of Gene Transfer and Expression of Human Clotting Factor IX in Hemophilia B Mice Mediated by Mini-Adenoviral Vector.

Preparation of A Recombinant Adeno-Associated Viral Vector with A Mutation of Human Factor Ix in Large Scale and Its Expression in Vitro and in Vivo

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Optimized Human Factor IX Expression Cassettes for Hepatic-Directed Gene Therapy of Hemophilia B

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Expression of Human Clotting Factor Ix Mediated by Recombinant Lentiviral Vector in Cultured Cells and Hemophilia B Mice

Hybrid Retroviral Vector with MCK Enhancers Inserted in LTR for Stable and Specific Expression of Human Factor IX in Skeletal Muscle.

Gene Therapy for Hemophilia B with Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

Injecting Skin Fibroblasts into Muscles to Express Human Clotting Factor IX Cdna.

Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.

Preparation of Raav/hflx by HSV/AAV Hybrid Helper Virus and Evaluation of Its Safety

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Efficient Delivery of Human Clotting Factor Ix after Injection of Lentiviral Vectors in Utero

[Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration]

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus